Vermillion, Inc. (NASDAQ:VRML) was downgraded by research analysts at ValuEngine from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday.
Separately, Canaccord Genuity boosted their target price on shares of Vermillion from $1.75 to $2.25 and gave the company a “buy” rating in a report on Thursday, November 2nd.
Vermillion (NASDAQ VRML) opened at $1.43 on Wednesday. Vermillion has a 52-week low of $0.91 and a 52-week high of $2.85. The company has a quick ratio of 3.67, a current ratio of 3.74 and a debt-to-equity ratio of 0.26.
Vermillion (NASDAQ:VRML) last posted its earnings results on Wednesday, November 8th. The company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.02). The firm had revenue of $0.70 million during the quarter. Vermillion had a negative net margin of 332.10% and a negative return on equity of 200.44%.
ILLEGAL ACTIVITY WARNING: “Vermillion, Inc. (VRML) Lowered to “Sell” at ValuEngine” was posted by Stock Observer and is the sole property of of Stock Observer. If you are accessing this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be accessed at https://www.thestockobserver.com/2017/11/15/vermillion-inc-vrml-lowered-to-sell-at-valuengine.html.
A number of large investors have recently bought and sold shares of VRML. Vanguard Group Inc. boosted its holdings in Vermillion by 0.7% in the 2nd quarter. Vanguard Group Inc. now owns 580,484 shares of the company’s stock valued at $1,068,000 after purchasing an additional 4,200 shares during the last quarter. Essex Investment Management Co. LLC boosted its holdings in Vermillion by 145.8% in the 3rd quarter. Essex Investment Management Co. LLC now owns 216,607 shares of the company’s stock valued at $390,000 after purchasing an additional 128,494 shares during the last quarter. Finally, Birchview Capital LP boosted its holdings in Vermillion by 7.9% in the 3rd quarter. Birchview Capital LP now owns 2,462,933 shares of the company’s stock valued at $4,433,000 after purchasing an additional 180,000 shares during the last quarter. Institutional investors own 33.79% of the company’s stock.
Vermillion Company Profile
Vermillion, Inc is a diagnostic service and bio-analytic solutions provider. The Company is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. It sells OVA1 risk of malignancy test for pelvic mass disease (OVA1). OVA1 is a blood test designed to, in addition to a physician’s clinical assessment of a woman with a pelvic mass, identify women who are at risk of having a malignant ovarian tumor prior to planned surgery.
Receive News & Ratings for Vermillion Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vermillion Inc. and related companies with MarketBeat.com's FREE daily email newsletter.